were studied in ea prean (n = 7; length of gestation, 8.6 1.5 weeks, mean drd deviaton), in late preg y (n = 7; length of gestation, 38.7 ± 1.4 weeks), and In the nonpregnant state (n = 6). A It has been confirmed that for many antibiotics, such as ampicillin and piperacillin, the pharmacokinetics alter and elimination is enhanced during pregnancy (10, 16) . This applies especially for polar drugs, and in general, the higher the water solubility of a drug is, the more its half-life is shortened during prepancy, while the reverse is true for lipid-soluble drugs (18). However, the pharmacokinetic behavior of a drug during pregnancy does not stick to the model predicted by the physicochemical properties only, as demonstrated in our previous study on the pharmacokinetics of medillinam (11).
It has been confirmed that for many antibiotics, such as ampicillin and piperacillin, the pharmacokinetics alter and elimination is enhanced during pregnancy (10, 16) . This applies especially for polar drugs, and in general, the higher the water solubility of a drug is, the more its half-life is shortened during prepancy, while the reverse is true for lipid-soluble drugs (18) . However, the pharmacokinetic behavior of a drug during pregnancy does not stick to the model predicted by the physicochemical properties only, as demonstrated in our previous study on the pharmacokinetics of medillinam (11) .
Imipenem is a fairly new carbapenem beta-lactam antibiotic which is clinically used in a 1:1 combination with cilastatin, a competitive inhibitor of dehydropeptidase, minimizing the renal metabolism of imipenem (2, 15) . It is active against a broad spectrum of bacteria, including all the common members of the family Enterobacteriaceae (MIC < 1.3 iLg/ml) and staphylococci (MIC < 2 pgfml) (20) , as well as Listeria monocytogenes (MIC for 90% of strains = 0.11 ig/ml [4] ; MIC < 0.25 ,.g/ml [8] ), Neisseria gonoeae (MIC for 90% of strains < 0.30 i&g/ml [4] ; MIC = 0.01 to 0.1 p,g/ml [3] ), Chlamydia trachomatis (3), and Bacteroides fi-agilis (MIC for 90% of strains = 0.25 pg/ml) (5) . There appear to be three previous studies on imipenem in the perinatal period. The transfer of the drug through placenta has been observed, and drug concentrations in the umbilical cord plasma and amniotic fluid were found to exceed MICs against main pathogenic organisms (6, 12, 14 Figure 1 shows a semilogarithmic plot of mean plasma imipenem concentrations versus time of women in early prepancy, women in late pregnancy, and nonpregnant women. The peak level in plasma achieved immediately after the infusion was significantly lower during pregnancy (mean ± SD, 14.7 + 4.9 and 14.9 ± 5.2 ,g/ml in early and late pregnancy, respectively) than in the nonpregnant state (43 ± 28 ,ug/ml; P < 0.05). At 2 h, the concentrations in plasma during pregnancy were still significantly lower than in the nonpregnant state (1.3 ± 0.9, 1.3 ± 0.8, and 2.9 ± 0.9 ,g/ml; P < 0.05). At 8 h after the dose, levels were unmeasurable (<0.02 ,g/ml) in most subjects and the highest levels observed were 0.15 ,ug/ml in early pregnancy and 0.08 pg/ml in the nonpregnant state. Table 2 shows the pharmacokinetic parameters calculated for imipenem. The apparent volume of distribution in 1 phase was significantly larger (P < 0.05) during pregnancy than in the nonpregant state. Imipenem was also cleared from the plasma significantly faster during pregnancy, at average rates of 0.7 ± 0.4 liter/min or 13 ± 8 ml min-' kg of body weight-1 (P < 0.05) in early pregnancy and of 1.0 ± 0.5 ml min-1 (P < 0.005) or 11 ± 5 ml min-1 kg-' (P < 0.05) in late pregnancy, than in the nonpregnant state, 0. 36 ± 8 643 ± 326t 301 ± 69t 3.8 ± 1.8 14.9 ± 5.2t C (6) 18.9 ± 5.8*t 0.3 ± 0.1*t 338 ± 85*t 6 ± 1*t 41 ± 16 1,548 ± 339*t 110 ± 43*t 2.0 ± 0.4 43.0 ± 28.3*t I Abbreviations: V, volume of distribution associated with 3 phase; CL, total clearance from plasma; tl2p, half-life at , phase; AUC, area under the concentration-time curve; CLR, renal clearance; Cn,,., maximum concentration of drug in serum. Significant differences (P < 0.05) between the groups are marked (* and t).
RESULTS
'a time curve was significantly smaller (P < 0.05) during pregnancy than in the nonpregnant state. The mean half-life at 1B phase in plasma did not differ significantly among the pregnant and nonpregnant women.
Imipenem passes the placenta in considerable quantity. The concentration in amniotic fluid varied greatly and was approximately (mean ± SD) 47% ± 39% of the simultaneous maternal concentration in plasma when sampled 3 h after the infusion in early pregnancy and 16% ± 25% when sampled 30 min after the infusion in late pregnancy. The imipenem mean concentration in umbilical venous and arterial blood was (mean ± SD) 33% ± 12% and 31% ± 13% of that in the maternal blood (Table 3) .
DISCUSSION
Imipenem has an extended spectrum of antimicrobial activity, excellent pharmacokinetic properties in nonpregnant subjects, and low toxicity (1) . No accumulation of imipenem has been noted in treatment of full-term infants (15) . Imipenem is considered effective and safe in treating perinatal infections (6) , and it has also been used for premature infants (17) .
In pregnancy, the MICs of imipenem for the most common pathogens prevail only for 2 h, while in the nonpregnant state the mean concentration in plasma remains above or at the MIC for 3 h after the infusion. Most strains of L. monocytogenes are susceptible to as little as 0.25 p,g of imipenem per ml (9) , and concentrations at or above this value are observed for as long as 5 h after the infusion as well as in early pregnancy (mean t SD, 0.3 ± 0.2 ,ug/ml) as in the nonpregnant state (0.4 ± 0.3 ,ug/ml) but in late pregnancy are observed only for 3 h (0.5 ± 0.4 ,ug/ml).
The pharmacokinetic characteristics for the nonpregnant women correspond well to those reported previously (13) . During pregnancy, however, many of the observed parameters differ significantly from those in the nonpregnant state. The enlarged apparent volume of distribution is only partially explained by the increased body weight associated with late pregnancy (Table 1) . Imipenem is likely to be distributed efficiently into the feto-maternal compartment, since the degree of protein binding in plasma is low, 13 to 21% (7, 18) . The clearance of imipenem from plasma is accelerated, while the renal clearance is not consistently changed, suggesting accelerated nonrenal clearance of imipenem during pregnancy. The half-life of imipenem, being dependent on both volume of distribution and clearance from plasma, does not vary considerably among the pregnant and nonpregnant subjects.
The transplacental passage of imipenem is noted, and even therapeutic concentrations are achieved in umbilical blood and amniotic fluid during late pregnancy. At 30 min after the infusion the ratio of the umbilical venous and arterial drug concentrations is 1.05, almost a state of equilibrium. The elimination of imipenem from the amniotic fluid seems to be slow, since as late as 3 h after the infusion the feto-maternal ratio is approximately 47% (in early pregnancy). The ratio of umbilical venous blood drug concentration to simultaneous maternal concentration in plasma was 33% 30 min after the start of the infusion. The same ratio has been reported by Hirabayashi and Okada to be 30% at the end of a 30-min infusion of 500 mg of imipenem (12) .
In conclusion, the pharmacokinetics of imipenem change considerably during pregnancy. An adjustment of the dose should be considered when treating pregnant women with serious infections.
